炭素(Charcoal) - 药物靶点：NF-κB_在研适应症：瘙痒，慢性肾病，尿毒症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Kremezin、Zysa

+ [5]

靶点

NF-κB

作用机制

NF-κB抑制剂(核因子NF-κB复合体抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Mitsubishi Tanabe Pharma Corp.

非在研机构

OCERA Therapeutics LLC

Kureha Corp.

Orion Pharma Ltd.

最高研发阶段批准上市

首次获批日期

日本 (1991-10-04),

慢性肾病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

关联

57

项与炭素相关的临床试验

NCT06595121 / Completed临床1期

Comparative Bioavailability Study of Budesonide After Inhalation of Budesonide 1 Mg / 2 Ml Nebuliser Suspension (Test Product 08P1707F0): Administration Without and with Activated Charcoal and Inhalation of Pulmicort® 1.0 Mg / 2 Ml Suspension (Reference Product) in Healthy Subjects

This study aims to demonstrate the bioequivalence between the formulation of Budesonide 1mg/2mL nebuliser suspension (IMP 08P1707F0) relaive to the reference product Pulmicort(r) 1.0mg/2mL suspension.

开始日期2024-08-13

申办/合作机构

Unither Pharmaceuticals SASU

[+1]

NCT06141473 / Recruiting临床3期

Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
Study details include:
* This event-driven study will have variable duration of approximately 40 months for the first participant being randomized and approximately 20 months for the last participant randomized.
* The study intervention duration will vary ranging from approximately 12 to 40 months.
* The assessment of scheduled visits will include 1 common end of study [EOS] visit and 3 follow-up visits) with a visit frequency of every 4 weeks for the first 6 months and then every 3 months.

开始日期2023-12-13

申办/合作机构

Sanofi

NCT06219967 / Completed临床4期IIT

Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Efficacy: A Randomized Crossover Trial

Activated charcoal (AC) is an established, effective means of gastrointestinal decontamination. Providers give it to patients who have ingested something that is thought to be potentially poisonous to prevent it from being absorbed. However, one limitation to its use is palatability of the AC for the patient, potentially limiting how much, if any, is taken.
Other studies have suggested that mixing AC with various substances improves the rating on various scales (taste, etc). An important question is whether mixing the AC with other substance effects the ability of the AC to bind to xenobiotic in the gut. This small study investigates whether mixed cola with charcoal affected its ability to prevent the absorption of acetaminophen. It also performs a survery to see if participants preferred the AC-cola mixture. The investigators hypothesize that the AC will be equally as effective with cola as without. The investigators also hypothesize that participants will prefer the AC-cola mixture.

开始日期2023-01-04

申办/合作机构

SUNY Upstate Medical University

100 项与炭素相关的临床结果

登录后查看更多信息

100 项与炭素相关的转化医学

登录后查看更多信息

100 项与炭素相关的专利（医药）

登录后查看更多信息

310

项与炭素相关的文献（医药）

2024-03-31·Kidney Research and Clinical Practice

Pharmacologic therapeutics in sarcopenia with chronic kidney disease

Article

作者: Cha, Ran-Hui

Inflammation, metabolic acidosis, renin-angiotensin system activation, insulin resistance, and impaired perfusion to skeletal muscles, among others, are possible causes of uremic sarcopenia. These conditions induce the activation of the nuclear factor-kappa B and mitogen-activated protein kinase pathways, adenosine triphosphate ubiquitin-proteasome system, and reactive oxygen species system, resulting in protein catabolism. Strategies for the prevention and treatment of sarcopenia in chronic kidney disease (CKD) are aerobic and resistance exercises along with nutritional interventions. Anabolic hormones have shown beneficial effects. Megestrol acetate increased weight, protein catabolic rate, and albumin concentration, and it increased intracellular water component and muscle mass. Vitamin D supplementation showed improvement in physical function, muscle strength, and muscle mass. Correction of metabolic acidosis showed an increase in protein intake, serum albumin levels, body weight, and mid-arm circumference. The kidney- gut-muscle axis indicates that dysbiosis and changes in gut-derived uremic toxins and short-chain fatty acids affect muscle mass, composition, strength, and functional capacity. Biotic supplements, AST-120 administration, hemodiafiltration, and preservation of residual renal function are alleged to reduce uremic toxins, including indoxyl sulfate (IS) and p-cresyl sulfate (PCS). Synbiotics reversed the microbiota change in CKD patients and decreased uremic toxins. AST-120 administration changed the overall gut microbiota composition in CKD. AST-120 prevented IS and PCS tissue accumulation, ameliorated muscle atrophy, improved exercise capacity and mitochondrial biogenesis, restored epithelial tight junction proteins, and reduced plasma endotoxin levels and markers of oxidative stress and inflammation. In a human study, the addition of AST-120 to standard treatment had modest beneficial effects on gait speed change and quality of life.

2024-02-01·Heliyon

Colonic microflora and plasma metabolite-based comparative analysis of unilateral ureteral obstruction-induced chronic kidney disease after treatment with the Chinese medicine FuZhengHuaYuJiangZhuTongLuo and AST-120

Article

作者: Wu, Shaobo ; Huang, Li ; Chen, Ming ; Chen, Ziwei ; Zeng, Yu ; Li, Xueying ; Li, Jing ; Chen, Zejun

BackgroundMany researchers have investigated the use of Chinese herbs to delay the progression of chronic kidney disease (CKD) through their effects on colonic microflora and microbiota-derived metabolites. However, whether FuZhengHuaYuJiangZhuTongLuo (FZHY) has effects that are similar to those of AST-120 on CKD needs to be elucidated.MethodsIn this study, we compared the effects of FZHY and AST-120 on the colonic microbiota and plasma metabolites in the CKD rat model. We developed a unilateral ureteral obstruction (UUO)-induced CKD rat model and then administered FZHY and AST-120 to these model rats. Non-targeted metabolomic LC-MS analysis, 16S rRNA sequencing, and histopathological staining were performed on plasma, stool, and kidney tissues, respectively, and the joint correlation between biomarkers and metabolites of candidate bacteria was analyzed.ResultsOur results showed that administering FZHY and AST-120 effectively ameliorated UUO-induced abnormal renal function and renal fibrosis and regulated the composition of microbiota and metabolites. Compared to the UUO model group, the p_Firmicutes and o_Peptostreptococcales_Tissierellales were increased, while 14 negative ion metabolites were upregulated and 21 were downregulated after FZHY treatment. Additionally, 40 positive ion metabolites were upregulated and 63 were downregulated. On the other hand, AST-120 treatment resulted in an increase in the levels of g_Prevotellaceae_NK3B31_group and f_Prevotellaceae, as well as 12 upregulated and 23 downregulated negative ion metabolites and 56 upregulated and 63 downregulated positive ion metabolites. Besides, FZHY increased the levels of candidate bacterial biomarkers that were found to be negatively correlated with some poisonous metabolites, such as 4-hydroxyretinoic acid, and positively correlated with beneficial metabolites, such as l-arginine. AST-120 increased the levels of candidate bacterial biomarkers that were negatively correlated with some toxic metabolites, such as glycoursodeoxycholic acid, 4-ethylphenol, and indole-3-acetic acid.ConclusionFZHY and AST-120 effectively reduced kidney damage, in which, the recovery of some dysregulated bacteria and metabolites are probably involved. As their mechanisms of regulation were different, FZHY might play a complementary role to AST-120 in treating CKD.

2023-07-10·Kidney research and clinical practice

Factors associated with gait speed: results from the RolE of AST120 (Renamezin) in sarCOpenia preVEntion in pRe-dialYsis chronic kidney disease patients (RECOVERY) study.

Article

作者: Kim, Su Hyun ; Kang, Seock Hui ; Kim, Jun Chul ; Cha, Ran-Hui ; Han, Miyeun ; Song, Sang Heon ; An, Won Suk

BackgroundGait speed is an important measure of functional ability. This study aimed to investigate the factors associated with gait speed in patients with chronic kidney disease. The study focused on sarcopenic components, plasma uremic or inflammatory marker levels, and quality of life effects.MethodsThe RolE of AST120 (Renamezin) in sarCOpenia preVEntion in pRe-dialYsis chronic kidney disease patients is a 48-week, randomized controlled, parallel-group, open-label, multicenter trial to determine the role of Renamezin (Daewon Pharmaceutical Co., Ltd.) in patients with chronic kidney disease. The participants were classified into four groups according to gait speed: ≤0.8, 0.8-1.0, ≤1.0-1.3, and ≥1.3 m/sec. Linear regression analysis was performed to identify the factors associated with gait speed.ResultsThe group with a gait speed of ≤0.8 m/sec was the oldest and had the highest proportion of participants with low education level and medical aid. Participants with a gait speed of ≤0.8 m/sec showed the lowest physical and mental component scale scores. The interleukin-6 (IL-6) level tended to be the higher trend in the lowest gait speed group. In the multivariate linear regression analysis adjusted for age, sex, diabetes mellitus, and estimated glomerular filtration rate, insurance status, handgrip strength, IL-6 level, hemoglobin level, mental component scale score, and physical component scale score were significantly associated with gait speed.ConclusionIn conclusion, gait speed is associated with handgrip strength, IL-6 level, and various components of quality of life in predialysis chronic kidney disease patients.

1

项与炭素相关的新闻（医药）

2022-07-26

·生物谷

Front Nutr：酸性活性炭或能帮助预防机体体重增加及胰岛素耐受性的发生

来自日本信州大学医学院等机构的科学家们通过研究发现，可食用的活性炭或许还会吸收饮食中过多的脂肪，文章中，研究人员验证了来自信州大学的赤松树所产生的酸性活性炭对小鼠的影响和安全性。随着人类饮食习惯的西方化，目前全球各地肥胖人口的比例都在不断增加，肥胖是一个人类面临的迫切的健康问题，同时也是导致多种疾病发生的风险因素，比如糖尿病、脂肪肝和血脂异常等。众所周知，可食用的活性炭能在肠道中吸收尿液毒素和胆汁酸，并以粪便的形式将其排出体外。近日，一篇发表在国际杂志Frontiers in Nutrition上题为“Acidic Activated Charcoal Prevents Obesity and Insulin Resistance in High-Fat Diet-Fed Mice”的研究报告中，来自日本信州大学医学院等机构的科学家们通过研究发现，可食用的活性炭或许还会吸收饮食中过多的脂肪，文章中，研究人员验证了来自信州大学的赤松树所产生的酸性活性炭对小鼠的影响和安全性。当小鼠被给予正常饮食和高脂肪饮食长达12周时，喂食高脂肪饮食的小鼠相比正常饮食的小鼠而言能体重会明显增加，从另一方面来讲，当酸性活性炭与高脂肪饮食混合后，以同样的方式喂食小鼠，其体重增加的程度几乎与正常饮食相同，这意味着，因高脂肪饮食所导致的体重增加会被完全抑制。当酸性活性炭与高脂肪饮食一起让小鼠摄入时，其粪便中胆汁酸、胆固醇、甘油三酯和脂肪酸的水平要比常规高脂肪饮食增加大约2-4倍，这或许会被认为其会促进在粪便中的排出，此外，研究人员并未观察到酸性活性炭对小鼠机体胃肠道或肺部的损伤。酸性活性炭或能帮助预防机体体重增加及胰岛素耐受性的发生。图片来源：Naoki Tanaka, Shinshu University 将酸性活性炭与高脂肪食物一起摄入，或在进食前摄入酸性活性炭或许能有效预防机体体重增加，基于从这项研究中得到的研究结果，研究人员希望能促进开发更有效且安全性的酸性活性炭，同时与当地和全球的公司合作，来开发出更有效的预防性措施来抵御疾病。长期以来，制作木炭在信州广泛流行，利用这类技术所产生的活性炭同样被用于除臭和净水，本文研究表明，来自赤松树中的酸性活性炭或能预防因高脂肪饮食所导致的小鼠体重增加和胰岛素耐受，通过将酸性活性炭加入到日常饮食中，或许就能有效预防人类肥胖、脂肪肝和糖尿病的发生，这些疾病近年来在全球的流行率不断增加。后期研究人员将会继续深入研究来讲来自赤松树中的酸性活性炭应用于医疗健康研究领域，综上，本文研究结果表明，酸性活性炭或许具有预防肥胖、代谢综合征及其相关疾病的重要特性。（生物谷Bioon.com）原始出处： Xuguang Zhang, Pan Diao, Hiroaki Yokoyama, et al. Acidic Activated Charcoal Prevents Obesity and Insulin Resistance in High-Fat Diet-Fed Mice, Frontiers in Nutrition (2022). DOI: 10.3389/fnut.2022.852767

100 项与炭素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A07BA01	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
瘙痒	中国台湾	-	2020-07-26
慢性肾病	日本	Mitsubishi Tanabe Pharma Corp.	1991-10-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
尿毒症	申请上市	-	HK inno.N Corp.	-
克罗恩病引起的肛周瘘	临床2期	比利时	OCERA Therapeutics LLC	2006-03-01
克罗恩病引起的肛周瘘	临床2期	奥地利	OCERA Therapeutics LLC	2006-03-01
克罗恩病引起的肛周瘘	临床2期	波兰	OCERA Therapeutics LLC	2006-03-01
克罗恩病引起的肛周瘘	临床2期	英国	OCERA Therapeutics LLC	2006-03-01
克罗恩病引起的肛周瘘	临床2期	德国	OCERA Therapeutics LLC	2006-03-01
克罗恩病引起的肛周瘘	临床2期	美国	OCERA Therapeutics LLC	2006-03-01
克罗恩病引起的肛周瘘	临床2期	匈牙利	OCERA Therapeutics LLC	2006-03-01
克罗恩病	临床2期	欧盟	OCERA Therapeutics LLC	-
克罗恩病引起的肛周瘘	临床1期	加拿大	OCERA Therapeutics LLC	2006-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


RolE of AST120 in sarCOpenia preVEntion in pRe-dialYsis chronic kidney disease patients (ERA2022)	N/A	慢性肾病 plasma uremic \| inflammatory markers	150	AST120	襯鏇餘製鏇簾鏇築淵鹹(顧憲製製觸鑰窪網範醖) = 艱願鏇齋窪膚簾願齋選鑰觸窪淵顧網餘製鹹糧 (壓獵範廠鹹簾願衊獵膚, 0.3)	-	2022-05-03
				AST120	襯鏇餘製鏇簾鏇築淵鹹(顧憲製製觸鑰窪網範醖) = 夢衊鹹憲構簾蓋糧鹹糧鑰觸窪淵顧網餘製鹹糧 (壓獵範廠鹹簾願衊獵膚, 0.3)
NCT01609218 (CTgov)	临床1期	-	27	LY2140023 (80 mg LY2140023)	構衊願顧蓋壓願鹹餘壓(顧獵範餘繭範蓋繭襯構) = 網鹹壓積製鑰鏇遞糧選顧選選鏇鑰選網築蓋鏇 (觸繭醖夢繭膚淵構餘願, 製築鬱鏇餘獵選艱遞範 ~ 淵衊製糧淵壓願繭鏇夢) 更多	-	2021-09-21
				Aqueous activated charcoal+LY2140023 (80 mg LY2140023 + 75 g Aqueous Activated Charcoal)	構衊願顧蓋壓願鹹餘壓(顧獵範餘繭範蓋繭襯構) = 遞醖糧襯鬱鑰廠積鹽衊顧選選鏇鑰選網築蓋鏇 (觸繭醖夢繭膚淵構餘願, 衊願糧糧繭壓製憲積範 ~ 觸鑰憲遞衊構選鑰衊淵) 更多
AST-120 (ASN2019)	N/A	-	225	AST-120	糧鹽網夢選艱顧積顧製(蓋夢淵壓膚構範繭廠糧) = 膚顧製鏇衊顧積鹹範糧齋窪願廠簾構鬱鬱壓觸 (簾築遞鬱窪鏇蓋襯鏇鏇 ) 更多	积极	2019-11-05
ASN2018	N/A	-	218	AST-120	範餘鬱鹹選壓淵鑰顧蓋(顧齋鏇簾鏇製齋壓鏇鏇) = 遞膚製鹹願壓鹹襯鹽願積餘夢襯醖廠鏇積膚糧 (觸鑰構鑰網憲壓範糧選 ) 更多	积极	2018-10-23
NCT00500682 \| NCT00501046 (EPPIC, Pubmed \| BMC Nephrol)	临床3期	慢性肾病	2,035	AST-120	獵膚壓鏇範製製壓築糧(鏇遞齋憲夢遞鬱繭製簾): Hazard Ratio = 0.74 (95% CI, 0.56 ~ 0.97)	-	2016-09-30
				Placebo
NCT00501046 (EPPIC-2, Pubmed \| J Am Soc Nephrol) 人工标引	临床3期	慢性肾病	2,035	AST-120	(簾範網遞壓壓糧簾襯艱): HR = 0.91 (95% CI, 0.74 ~ 1.12), P-Value = 0.37	不佳	2015-07-01
				Placebo
NCT00500682 (EPPIC-1, CTgov)	临床3期	慢性肾病	1,020	AST-120 (AST-120)	窪積獵鹽願積遞選膚網(簾鏇鏇積夢餘鏇築網鏇) = 淵構襯鏇鏇蓋壓繭糧蓋淵膚壓積鹹鑰築鑰窪廠 (遞鬱鑰窪醖觸積積齋醖, 鑰簾鑰構蓋餘艱遞壓繭 ~ 簾艱範積夢壓鑰遞簾範) 更多	-	2015-03-02
				Placebo (Placebo)	窪積獵鹽願積遞選膚網(簾鏇鏇積夢餘鏇築網鏇) = 獵顧窪廠艱簾築廠壓衊淵膚壓積鹹鑰築鑰窪廠 (遞鬱鑰窪醖觸積積齋醖, 鏇顧觸獵壓廠顧糧簾糧 ~ 網憲範膚淵鏇網積衊艱) 更多
NCT00501046 (EPPIC-2, CTgov)	临床3期	慢性肾病	1,015	AST-120 (AST-120)	選夢鑰淵襯襯淵窪襯獵(選襯鹹簾廠積醖鹽網觸) = 蓋淵願艱觸鑰憲鹹鑰網淵遞壓遞廠網觸選餘願 (膚鬱淵鑰鏇網襯膚獵構, 廠醖襯願遞鹹廠壓醖顧 ~ 獵齋網壓壓鏇餘齋鬱襯) 更多	-	2015-03-02
				Placebo (Placebo)	選夢鑰淵襯襯淵窪襯獵(選襯鹹簾廠積醖鹽網觸) = 顧夢淵壓繭獵選構淵選淵遞壓遞廠網觸選餘願 (膚鬱淵鑰鏇網襯膚獵構, 獵襯憲餘蓋鑰鹹糧窪顧 ~ 壓餘顧築廠築餘鏇觸簾) 更多
ASN2012	N/A	霍奇金淋巴瘤 Indoxyl sulfate	-	AST-120	願壓積選鬱艱築糧鹹構(淵觸餘淵網廠獵顧廠積) = No specific side effect from AST-120 was not reported 選鬱觸淵願齋衊齋夢繭 (醖衊製夢範遞艱餘艱憲 ) 更多	积极	2012-10-30
ASN2011	N/A	慢性肾病 indoxyl sulfate	200	AST-120	夢觸膚鹹廠簾鏇顧齋餘(網艱築壓鏇積窪積願廠) = 網醖蓋鏇獵製壓製製繭選鹹顧鑰範鹽膚鑰齋顧 (壓齋艱繭鑰遞觸憲壓醖, 2.5 ~ 30.3)	积极	2011-11-08